|
Volumn 10, Issue 6, 2000, Pages 229-237
|
Human urotensin-II, the most potent mammalian vasoconstrictor identified To date, as a therapeutic target for the management of cardiovascular disease
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ENDOTHELIN 1;
G PROTEIN COUPLED RECEPTOR;
SEROTONIN;
SPASMOGEN;
UNCLASSIFIED DRUG;
UROTENSIN II;
UROTENSIN II RECEPTOR;
UROTENSIN II RECEPTOR ANTAGONIST;
VASOCONSTRICTOR AGENT;
ATHEROMA;
BLOOD VESSEL;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR SYSTEM;
CONGESTIVE HEART FAILURE;
CORONARY ARTERY ATHEROSCLEROSIS;
DOG;
HEART DISEASE;
HEART INFARCTION;
HEART MUSCLE;
HEART MUSCLE CONTRACTILITY;
HEART STROKE VOLUME;
HEART VENTRICLE REMODELING;
HEMODYNAMICS;
HOMEOSTASIS;
HUMAN;
ISOLATED ARTERY;
MAMMAL;
MOLECULAR CLONING;
MOUSE;
NONHUMAN;
PATHOPHYSIOLOGY;
PRIMATE;
PRIORITY JOURNAL;
RABBIT;
RAT;
REVIEW;
SHOCK;
SWINE;
VASCULAR ENDOTHELIUM;
VASCULAR RESISTANCE;
VASCULAR SMOOTH MUSCLE;
VASOCONSTRICTION;
ANIMALS;
BLOOD VESSELS;
CARDIOVASCULAR DISEASES;
CARDIOVASCULAR SYSTEM;
HEMODYNAMIC PROCESSES;
HUMANS;
RECEPTORS, CELL SURFACE;
RECEPTORS, G-PROTEIN-COUPLED;
SPECIES SPECIFICITY;
UROTENSINS;
VASOCONSTRICTOR AGENTS;
|
EID: 0034466374
PISSN: 10501738
EISSN: None
Source Type: Journal
DOI: 10.1016/S1050-1738(00)00069-4 Document Type: Review |
Times cited : (196)
|
References (45)
|